EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy

On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma’s drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy.

In making its recommendation, the Committee reviewed data from four studies of pitolisant—two placebo-controlled trials (N = 259), one uncontrolled open-label study (N = 102), and one additional study that provided supportive data (N = 105).

Pitolisant is different from any other medication that is currently approved to treat the excessive daytime sleepiness and cataplexy associated with narcolepsy. Through its action on histamine H3 receptors in the brain, this drug increases the release of histamine in the brain, thereby increasing wakefulness and alertness. In one study, pitolisant was also found to slightly decrease the incidence of cataplexy.

Pitolisant will not be immediately available for sale. The next step is for the CHMP opinion to be sent to the European Commission, who will then decide whether to adopt this decision and authorize marketing throughout the European Union. If the European Commission authorizes marketing, each member of the European Union will then decide on whether they will make pitolisant available in their national health system and at what price.

For more information on the role of histamine in controlling wakefulness, please see the August 18, 2015, issue of SomnusNooze, “How GABA and histamine work together to control wakefulness.”

emea_strap_url_cmyk_rev_en_std_cent.eps MASTER

Share Post

SomnusNooze Home Page

SomnusNooze Editions/Archives
Disclaimer

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.